Experienced in Hereditary Hemorrhagic Telangiectasia

Dr. David J. Andorsky

Oncology
4715 Arapahoe Ave, 
Boulder, CO 
Accepting New Patients
Offers Telehealth
Experienced in Hereditary Hemorrhagic Telangiectasia
4715 Arapahoe Ave, 
Boulder, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Andorsky is an Oncologist in Boulder, Colorado. Dr. Andorsky is rated as an Experienced provider by MediFind in the treatment of Hereditary Hemorrhagic Telangiectasia. His top areas of expertise are Follicular Lymphoma, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Richter Syndrome. Dr. Andorsky is currently accepting new patients.

His clinical research consists of co-authoring 23 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Harvard Medical School
Residency
Brigham and Women's Hospital
Specialties
Oncology
Licenses
Internal Medicine in CA
Board Certifications
Internal Medicine-American Board Of Internal Medicine (ABIM)
Medical Oncology-American Board Of Internal Medicine (ABIM)
Hematology-American Board Of Internal Medicine (ABIM)
Fellowships
UCLA
Hospital Affiliations
Boulder Community Health
Centura Health-Avista Adventist Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Rocky Mountain Cancer Centers LLP
4715 Arapahoe Ave, Boulder, CO 80303

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Enrollment Status: Active_not_recruiting
Publish Date: November 21, 2025
Intervention Type: Drug
Study Drugs: Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib
Study Phase: Phase 3
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
An Open Label, Multi-center Phase IIIb Study of Asciminib (ABL001) Monotherapy in Previously Treated Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drug: ABL001
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers
Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers
Enrollment Status: Approved_for_marketing
Publish Date: December 18, 2024
Intervention Type: Drug
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: March 25, 2024
Intervention Type: Drug, Combination product
Study Drug: Tazemetostat
Study Phase: Phase 2
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

23 Total Publications

Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial.
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial.
Journal: Blood
Published: July 01, 2025
Similar Doctors
Experienced in Hereditary Hemorrhagic Telangiectasia
Dr. Lori L. Jensen
Oncology
Experienced in Hereditary Hemorrhagic Telangiectasia
Dr. Lori L. Jensen
Oncology

Rocky Mountain Cancer Centers LLP

4715 Arapahoe Ave, 
Boulder, CO 
 (0.1 miles away)
303-385-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lori Jensen is an Oncologist in Boulder, Colorado. Dr. Jensen is rated as an Advanced provider by MediFind in the treatment of Hereditary Hemorrhagic Telangiectasia. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Small Lymphocytic Lymphoma (SLL), and Inflammatory Breast Cancer. Dr. Jensen is currently accepting new patients.

Experienced in Hereditary Hemorrhagic Telangiectasia
Dr. Gregory J. Britt
Oncology
Experienced in Hereditary Hemorrhagic Telangiectasia
Dr. Gregory J. Britt
Oncology

Rocky Mountain Cancer Centers LLP

4715 Arapahoe Ave, 
Boulder, CO 
 (0.1 miles away)
303-385-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregory Britt is an Oncologist in Boulder, Colorado. Dr. Britt is rated as a Distinguished provider by MediFind in the treatment of Hereditary Hemorrhagic Telangiectasia. His top areas of expertise are Hodgkin Lymphoma, Acute Mountain Sickness, Adult Soft Tissue Sarcoma, and Childhood Iron Deficiency Anemia. Dr. Britt is currently accepting new patients.

Experienced in Hereditary Hemorrhagic Telangiectasia
Dr. Michael D. Stone
Oncology | Hematology Oncology | Hematology
Experienced in Hereditary Hemorrhagic Telangiectasia
Dr. Michael D. Stone
Oncology | Hematology Oncology | Hematology

Poudre Valley Medical Group LLC

1925 Mountain View Ave, 
Longmont, CO 
 (12.9 miles away)
303-776-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Stone is an Oncologist and a Hematologist Oncology provider in Longmont, Colorado. Dr. Stone is rated as a Distinguished provider by MediFind in the treatment of Hereditary Hemorrhagic Telangiectasia. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Stone is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Andorsky's expertise for a condition
ConditionClose
    View All 16 Distinguished Conditions
    View All 48 Advanced Conditions
    View All 152 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile